Dror Ben-Asher, CEO
Dror has extensive managerial and transactional expertise, He was previously with ProSeed Capital, a European corporate finance boutique. Dror is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Dror was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror received an LL.B. with distinction (First Class Honours) from the University of Leicester.
Ori Shilo, Deputy CEO, Finance and Operations
Ori has extensive financial and transactional expertise. He was previously with ProSeed Capital, the Israeli Antitrust Authority and Delloite & Touche Consulting. Ori received an MBA (Finance) from Ben Gurion University and a B.A. in Business Administration (Magna Cum Laude) from the College of Management, Tel-Aviv.
Reza Fathi PhD, Senior VP R&D
Prior to joining RedHill, Reza served as Director of Research Operations at XTL Biopharmaceuticals. He was previously at VivoQuest, PharmaGenics, Metrigen, Enzo Biochem and Harvard Institute of Chemistry and Cell Biology. Reza graduated from Rutgers University (Ph.D. and Post-Doctoral Fellow) and Texas Tech University (BSc).
Gilead Raday, Senior VP Product and Corporate Development
Gilead previously served as interim CEO of Sepal Pharma, and a director of TK Signal and Morria Biopharmaceuticals. He is a graduate of the University of Cambridge (Master’s in Bioscience Enterprise) and the Hebrew University of Jerusalem (MSc Neurobiology, BSc Mathematics and Biology).
Adi Frish, Senior VP Business Development and Licensing
Adi has extensive business development and transactional experience. Prior to joining RedHill, he served as VP Business Developement at Medigus (TASE: MDGS). Prior to that, Adi was a partner at Y. Ben-Dror & Co., and graduated from Bar Ilan University (LL.M.) and Essex University (LL.B. with Honors).
Guy Goldberg , Chief Business Officer
Prior to joining RedHill, Guy served as Senior Vice President of Business Operations at Eagle Pharmaceuticals, a specialty injectable drug development company, based in New Jersey. Previously, Guy was a member of the investment team at ProQuest Investments, a healthcare focused venture capital firm. Prior to that, he was a consultant at McKinsey & Company. Guy holds a B.A. in Economics and Philosophy from Yale University and a J.D. from Harvard Law School.
Ira Kalfus MD, Medical Director
Prior to joining RedHill, Ira was with Lev Pharmaceuticals (VP of Medical Affairs), Aetna/US Healthcare, Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement). He completed residency in Internal Medicine at LIJ and graduated from the Albert Einstein College of Medicine (M.D.) and Columbia University (B.A. in Biology).
Tom Lang PhD, VP Regulatory and Clinical Affairs
Prior to joining RedHill, Dr. Lang had over thirty years of experience in increasingly senior executive level positions in the pharmaceutical and biotech industry. He was previously with, among other companies, Serono (President and Vice Chairman, Serono Inc.), Ciba-Geigy, Janssen, Warner-Lambert, and Organon. Dr. Lang received a PhD (Management) from Columbus University, an MBA from Fairleigh Dickinson University, B.S. – Pharmacy from Rutgers University, and B.S – Chemistry from Fairleigh Dickinson University. Dr. Lang is also a registered pharmacist in the State of New Jersey.
Elkan Gamzu PhD, Product Manager
Prior to Joining RedHill, Elkan had thirty years of successful career in the pharmaceutical and biotech industry including senior executive positions. He was previously with, among others, Roche, Warner Lambert/Parke-Davis, Cambridge NeuroScience, Millennium, XTL Biopharmaceuticals and Hypnion. Elkan graduated with M.A. and Ph.D. in Psychology from the University of Pennsylvania and B.A. in Psycology and Sociology from the Hebrew University of Jerusalem.
Patrick Mclean, Product Manager
Prior to joining RedHill, Patrick accumulated extensive experience in various senior executive positions in pharmaceutical companies including Giaconda Limited (CEO and Acting Chairman), Axcan Pharma (Senior VP European Commercial Operations, VP Sales & Marketing, Canada & US), Cossette Health Group (General Manager) and Allard Pharma Communications (President). Patrick graduated from the University of Minnesota (B.S. Chemistry).
Clara Fehrmann, Director of Clinical Operations
Clara has extensive R&D experience in the pharmaceutical industry acquired across large pharma, biotech as well as contract research companies. Prior to joining RedHill, Clara served as Clinical Project Manager at Merck Canada, Inc. and in various drug development positions at Santhera Pharmaceuticals. Clara has also served as Clinical Research Associate at ICON Clinical Research (Canada), Inc. Clara graduated with B.Sc. in Microbiology and Immunology from McGill University in Montreal and holds an M.Sc. degree in Pharmaceutical Sciences from the University of Montreal, Canada.
Pascal Weerts, Director of Corporate and Legal Affairs
Pascal has extensive corporate finance and corporate governance experience. During his carreer as a lawyer, Pascal focused on corporate law and transactions, M&A, private equity and equity capital markets work. Prior to joining RedHill he was a Partner at Allen & Overy LLP, and was a foreign intern at Skadden Arps Slate Meagher and Flom LLP. Pascal graduated from the Catholic University of Leuven (Law).
Uri Hananel Aharon, Chief Accounting Officer
Uri previously served as a team manager at Ernst & Young as well as an accountant at BDO and has an extensive experience in auditing and financial consulting for companies traded in NASDAQ and on the Tel Aviv Stock Exchange, both in the biotech and high-tech sectors. Uri is a graduate of the Hebrew University (BA, Economics and Accounting) and the Academic College for Management, Rishon Lezion (MBA, Business Taxation).